-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Sign up for news updates
Industry News & Regulatory Approvals
-
Regulatory Approval Brings New Targeted Treatment Option for NSCLC to European Union
The European Commission recently approved adagrasib for KRAS G12C+ non-small cell lung cancer. Additionally, the US FDA has accepted a premarket approval application for tumor treating fields therapy.
-
In Brief for November 8, 2023
October saw two approvals from the US FDA as well as caution from the agency’s Oncologic Drug Advisory Committee regarding the interpretation of CodeBreak 200 data; Takeda announces withdrawal of mobocertinib.
-
In Brief for June 28, 2023
Canada to require health warnings on cigarettes. US FDA approves application for pemetrexed injection, grants priority review for repotrectinib.
-
In Brief for May 24, 2023
Health Canada gives greenlight to cemiplimab-chemo combo for first-line treatment of advanced NSCLC. Early registration for WCLC 23 ends June 9.
-
In Brief for April 26, 2023
US Food and Drug Administration grants Fast Track designation for novel mesothelioma therapy.
-
Pragmatic Approach to Trial Design Born from Lung-MAP Substudy
In a recent interview with ILCN, the US FDA’s Dr. Harpreet Singh discusses the confirmatory Pragmatica-Lung trial and how the agency’s new pragmatic approach to trial design can streamline research and ultimately benefit patients.
-
Narrow Focus Allows Pragmatica-Lung Trial to Minimize Eligibility Criteria, Significantly Reduce Data Collection, Researcher Says
In a recent interview with ILCN, Dr. Karen Reckamp discussed the overall survival implications from the phase II Lung-MAP study and how the phase III follow-up Pragmatica-Lung trial aims to confirm that specific endpoint.
-
In Brief for Feb. 8, 2023
Dr. Carolyn Dresler Joins Action on Smoking and Health (ASH) Board of Trustees; Novel Liquid Biopsy Assay for Lung Carcinoma Detection Receives FDA Breakthrough Device Designation.
-
In Brief for January 25, 2023
China approves mobocertinib for patients with EGFR Exon20 insertion+ NSCLC; Deadline approaching for IASLC 2023 Lectureship and Distinguished Service Award Nominations.
-
In Brief for Jan. 11, 2023
Japan greenlights durvalumab and tremelimumab in combination with chemotherapy; US approves companion diagnostic tool for certain TKIs and expands indications for pemetrexed injection.
View ILCN Archives
Provider Resources
Popular Articles